Related Experiment Videos
Estrogen mini-dose replacement during GnRH agonist therapy in central precocious puberty: a pilot study
Meir Lampit1, Avraham Golander, Hadassah Guttmann
1Department of Pediatrics, Rambam Medical Center, Haifa 31096, USA.
The Journal of Clinical Endocrinology and Metabolism
|February 12, 2002
Summary
Low estrogen levels during central precocious puberty (CPP) treatment with GnRH agonists can slow growth. A small dose of estrogen replacement therapy safely maintained normal growth in girls with CPP.
Area of Science:
- Pediatric Endocrinology
- Reproductive Endocrinology
Background:
- Central precocious puberty (CPP) treatment with GnRH agonists can lead to suppressed growth velocity.
- The role of estrogen suppression in this growth inhibition is not fully understood.
Purpose of the Study:
- To investigate the impact of estrogen suppression on growth in girls with CPP undergoing GnRH agonist therapy.
- To evaluate the efficacy and safety of low-dose estrogen replacement in normalizing growth during CPP treatment.
Main Methods:
- A pilot study compared 13 girls with CPP receiving GnRH agonist plus conjugated equine estrogen (group 1) versus GnRH agonist alone (group 2) for 2 years.
- Growth velocity and bone maturation were monitored in both groups.
Main Results:
- Group 1 maintained normal growth velocity (1.3 +/- 1.5 SD score), while group 2 showed decreased growth velocity (-1.6 +/- 1.2 SD score).
- The ratio of bone age to chronological age progression slowed in group 1 compared to group 2.
- Estradiol (E2) levels remained undetectable in both groups.
Conclusions:
- Estrogen suppression contributes to slow growth in girls with CPP treated with GnRH agonists.
- Low-dose estrogen replacement appears safe and effective for maintaining normal prepubertal growth without accelerating bone maturation or pubertal development in CPP patients.